Cannabis / CBD
Why THC Topicals Are Suddenly Trending Imagine rubbing relief onto a sore shoulder without the fog of a high. That simple promise has turned THC-infused creams, balms and gels into the hottest ticket on dispensary shelves this year. THC topicals are booming because they combine the therapeutic promise of cannabis
Cannabis / CBD
When the lights come on in a 10,000-sq-ft grow house, the first thing a seasoned cultivator hears isn’t the hum of fans but the sound of the electric meter ticking. In 2024, that click can be a badge of pride instead of a cost-center - if growers swap
Cannabis / CBD
Imagine spending months, even years, building a storefront that never opens because the government’s green light is stuck in a bureaucratic queue. That’s the reality for dozens of minority-owned cannabis ventures in New York, where a licensing backlog has turned ambition into a costly waiting game. As 2024
Cannabis / CBD
Financial Disclaimer: This article is for educational purposes only and does not constitute financial advice. Consult a licensed financial advisor before making investment decisions. The $30 B Banking Void - Why Dispensaries Struggle Picture a dispensary with cash stacked like a small vault, employees counting bundles behind the register, and
Cannabis / CBD
Picture this: Alaska’s budget office is juggling oil price volatility, rising education costs, and a growing demand for addiction-prevention programs. In the middle of that high-wire act sits a modest but reliable stream of cannabis tax dollars - until a proposed rollback threatens to cut that flow by almost
Cannabis / CBD
When the federal government finally nudged cannabis from the forbidden list to Schedule III in 2024, the headline was clear: a new regulatory chapter for growers and retailers. For investors, however, the real story lies in how that shift ripples through the balance sheets of cannabis real-estate investment trusts (REITs)
Cannabis / CBD
Picture this: a mid-cap cannabis company suddenly sheds the heavy regulatory ballast that has been dragging its cost of capital down like an anchor. In 2024, lawmakers are buzzing about a Schedule I-to-III reclassification, and the financial ripple effects could be as dramatic as a 30% discount-rate haircut. If you’
Cannabis / CBD
When a courtroom decision suddenly lifts a weight off a small business’s shoulders, the relief can be palpable - especially for dispensaries that have been watching the clock tick on looming fines. The March 15, 2024 ruling from the Michigan Court of Appeals did just that for Upper Michigan’
Cannabis / CBD
Why Seniors Are Turning to CBD for Joint Pain When the aches of arthritis start to dictate daily routines, many older adults are swapping pills for a plant-based alternative that won’t leave them drowsy or dependent. CBD offers a non-opioid option that eases arthritis discomfort while fitting seamlessly into
Cannabis / CBD
Imagine a researcher walking into a lab in 2025, laptop in hand, only to discover that the federal grant portal now lists cannabis alongside antibiotics and vaccines. That shift from “no medical use” to “eligible for funding” could happen sooner than most expect, thanks to a proposal from the Trump
Cannabis / CBD
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. The Current Schedule I Barrier: How Federal Classification Stifles Pediatric Research Because cannabis remains a Schedule I drug, any researcher who wants to study it
Cannabis / CBD
Imagine reaching for a gummy that promises calm without the headache of a surprise drug test. In 2024, more consumers are turning to CBD edibles, but the market remains a minefield of mislabeled products and hidden contaminants. Why Lab Testing Is the First Line of Defense Lab testing separates trustworthy